PMID- 9256133
OWN - NLM
STAT- MEDLINE
DCOM- 19970908
LR  - 20220420
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 15
IP  - 8
DP  - 1997 Aug
TI  - HER-2/neu gene amplification characterized by fluorescence in situ hybridization: 
      poor prognosis in node-negative breast carcinomas.
PG  - 2894-904
AB  - PURPOSE: The HER-2/neu gene codes for a membrane receptor protein that is 
      homologous, but distinct from the epidermal growth factor receptor. This 
      investigation was performed to validate fluorescence in situ hybridization (FISH) 
      as a sensitive and specific method for assessing HER-2/neu gene amplification in 
      archival tissue and to test whether this alteration is associated with poor 
      prognosis. MATERIALS AND METHODS: HER-2/neu gene amplification was determined by 
      FISH in 140 archival breast cancers, previously characterized for gene 
      amplification by Southern hybridization or dot-blot hybridization, and for gene 
      expression by Northern hybridization, Western immunoblot, or 
      immunohistochemistry. A separate cohort of 324 node-negative breast cancers was 
      assessed for amplification by FISH to determine the utility of HER-2/neu gene 
      amplification. RESULTS: Relative to solid-matrix blotting procedures, FISH 
      analysis of HER-2/neu gene amplification showed a sensitivity of 98% and a 
      specificity of 100% in 140 breast cancers. Among patients treated by surgery 
      only, the relative risks (relative hazard) of early recurrence (recurrent disease 
      within 24 months of diagnosis), recurrent disease (at any time), and 
      disease-related death were statistically significantly associated with 
      amplification. The prognostic information contributed by HER-2/neu amplification 
      was independent of the other markers studied. CONCLUSION: FISH was an alternative 
      technique for determining gene amplification and had some distinct advantages 
      over Southern hybridization. Our results demonstrate that HER-2/neu gene 
      amplification in the absence of adjuvant therapy is an independent predictor of 
      poor clinical outcome and is a stronger discriminant than tumor size. Women with 
      small tumors that had gene amplification were at increased risk of recurrence and 
      disease-related death.
FAU - Press, M F
AU  - Press MF
AD  - Norris Comprehensive Cancer Center and Department of Pathology, University of 
      Southern California School of Medicine, Los Angeles, CA 90033, USA. 
      villalob@hsc.usc.edu
FAU - Bernstein, L
AU  - Bernstein L
FAU - Thomas, P A
AU  - Thomas PA
FAU - Meisner, L F
AU  - Meisner LF
FAU - Zhou, J Y
AU  - Zhou JY
FAU - Ma, Y
AU  - Ma Y
FAU - Hung, G
AU  - Hung G
FAU - Robinson, R A
AU  - Robinson RA
FAU - Harris, C
AU  - Harris C
FAU - El-Naggar, A
AU  - El-Naggar A
FAU - Slamon, D J
AU  - Slamon DJ
FAU - Phillips, R N
AU  - Phillips RN
FAU - Ross, J S
AU  - Ross JS
FAU - Wolman, S R
AU  - Wolman SR
FAU - Flom, K J
AU  - Flom KJ
LA  - eng
GR  - CA48780/CA/NCI NIH HHS/United States
GR  - CA58197/CA/NCI NIH HHS/United States
GR  - N01-HD-3-3175/HD/NICHD NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - Breast Neoplasms/genetics/mortality/*pathology
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - Immunoblotting
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics
MH  - Sensitivity and Specificity
MH  - Survival Rate
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - 10.1200/JCO.1997.15.8.2894 [doi]
PST - ppublish
SO  - J Clin Oncol. 1997 Aug;15(8):2894-904. doi: 10.1200/JCO.1997.15.8.2894.